

Di Wu

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5742823/di-wu-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

23
papers

251
citations

7
h-index

15
g-index

28
ext. papers

331
ext. citations

4.3
avg, IF

2.44
L-index

#	Paper	IF	Citations
23	Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China. <i>Frontiers in Oncology</i> , 2021 , 11, 607531	5.3	2
22	Prognostic factor analysis of patients with small cell lung cancer: Real-world data from 988 patients. <i>Thoracic Cancer</i> , 2021 , 12, 1841-1850	3.2	2
21	Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 1	7.4	0
20	BacFlash signals acid-resistance gene expression in bacteria. <i>Cell Research</i> , 2021 , 31, 703-712	24.7	1
19	Comparison of endostatin combined with PT-DC versus bevacizumab combined with PT-DC in the first-line treatment of advanced lung adenocarcinoma: a retrospective propensity score-matched cohort study. <i>Annals of Palliative Medicine</i> , 2021 , 10, 7847-7856	1.7	1
18	Identification of serum biomarkers to predict pemetrexed/platinum chemotherapy efficacy for advanced lung adenocarcinoma patients by data-independent acquisition (DIA) mass spectrometry analysis with parallel reaction monitoring (PRM) verification. <i>Translational Lung Cancer Research</i> , 2021 , 10, 981-994	4.4	4
17	Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients. <i>Cancer Cell International</i> , 2020 , 20, 590	6.4	
16	A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer. <i>International Journal of Cancer</i> , 2020 , 147, 3453-3460	7.5	12
15	Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2020 , 26, 3975-3988	5.6	1
14	Salvage treatment with anlotinib for advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019 , 10, 1590-1596	15.20	0
13	Molecular analysis of cell-free DNA identifies distinct molecular features in patients with chemosensitive and chemorefractory small cell lung cancer. <i>Cancer Communications</i> , 2019 , 39, 20	9.4	4
12	Dbx2 exhibits a tumor-promoting function in hepatocellular carcinoma cell lines regulating Shh-Gli1 signaling. <i>World Journal of Gastroenterology</i> , 2019 , 25, 923-940	5.6	6
11	Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018 , 14, 446-452	1.9	18
10	Mitochondrial flashes regulate ATP homeostasis in the heart. <i>ELife</i> , 2017 , 6,	8.9	40
9	Prognostic value of a 12-gene signature in platinum-based chemotherapy treated SCLC.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20011-e20011	2.2	
8	Efficacy and safety of endostar in the treatment of advanced lung squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20574-e20574	2.2	
7	Regulation of Mitoflash Biogenesis and Signaling by Mitochondrial Dynamics. <i>Scientific Reports</i> , 2016 , 6, 32933	4.9	10

6	Clinical characteristics associated with non-small-cell lung cancer harboring ALK rearrangements in Chinese patients. <i>Future Oncology</i> , 2016 , 12, 1243-9	3.6	4
5	Clinical characteristics associated with metastatic NSCLC harboring ALK rearrangements in Chinese patients.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e20628-e20628	2.2	
4	Protons Trigger Mitochondrial Flashes. <i>Biophysical Journal</i> , 2016 , 111, 386-394	2.9	26
3	Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics. <i>Thoracic Cancer</i> , 2015 , 6, 534-8	3.2	86
2	Dynamic changes of circulating tumor cells during chemotherapy as a prognostic factor in patients with advanced lung cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e22024-e22024	2.2	
1	Retrospective study of surgery versus non-surgical management in limited-disease small cell lung cancer. <i>Thoracic Cancer</i> , 2014 , 5, 405-10	3.2	6